Shared Decision Making for Patients With First-admission Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT01869660
- Lead Sponsor
- Yokohama City University
- Brief Summary
To determine whether shared decision making (SDM) intervention improves patient satisfaction in patients with first-admission schizophrenia compared with usual care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Admitted to an acute care psychiatric ward.
- Diagnosed with schizophrenia (ICD-10 codes: F20-F29)
- Aged 16 to 65 years old at admission
- No prior experience of psychiatric admission (first-admission)
Exclusion Criteria
- Diagnosed with moderate to severe mental retardation
- Diagnosed with organic mental disorders (ICD10 codes: F00-F09)
- Having poor Japanese language skill
- Severe conceptual disorganization as measured by brief psychiatric rating scale of 5 or more.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Patient satisfaction as measured by the Japanese version of the Client Satisfaction Questionnaire (CSQ-8) Within 7days before the date of discharge
- Secondary Outcome Measures
Name Time Method Attitude toward medication as measured by the Japanese version of the Drug Attitude Inventory (DAI-10) Within 7days before the date of discharge Treatment continuation as measured by the rate of outpatient attendance during the 30 days 6 months after discharge
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie shared decision making's impact on patient satisfaction in first-admission schizophrenia?
How does SDM compare to standard antipsychotic treatment protocols in early psychosis outcomes?
Are there specific biomarkers associated with treatment adherence in first-episode schizophrenia patients?
What adverse events are commonly reported in behavioral intervention trials for schizophrenia populations?
What combination therapies show promise with SDM approaches for schizophrenia management?
Trial Locations
- Locations (1)
Numazu Chuou Hospital
🇯🇵Numazu, Shizuoka, Japan
Numazu Chuou Hospital🇯🇵Numazu, Shizuoka, Japan